The Role of Tumor Infiltrating Lymphocyte (TIL) Therapy in NSCLC

Adam J. Schoenfeld, MD, provides key insights into treatment options for patients with non–small cell lung cancer whose tumors progress after first-line therapy.

A key opinion leader in thoracic oncology discusses factors to consider regarding emerging cell therapy options in non–small cell lung cancer, such as CAR T, TCR, and TIL therapies.

An expert in the management of non–small cell lung cancer defines tumor-infiltrating lymphocyte (TIL) therapy by discussing its mechanism of action and reviewing its impact in other disease states, such as myeloma.

Adam J. Schoenfeld, MD, considers the benefits and limitations of tumor-infiltrating lymphocyte (TIL) therapy and discusses its potential impact on the treatment landscape in non–small cell lung cancer.

A key opinion leader in the management of lung cancer offers insight into ongoing clinical trials of tumor-infiltrating lymphocyte (TIL) therapy in non–small cell lung cancer.

An expert thoracic oncologist, Adam J. Schoenfeld, MD, highlights key factors that patients and providers should take into account when considering cell therapy in non–small cell lung cancer.